Biosimilar pegfilgrastim regulatory update

FDA issued a complete response letter to Novartis’ Sandoz Inc. generics unit for a BLA for LA-EP2006, its proposed biosimilar of neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN,...